Evaluación del uso de corticoides como un marcador de atención de calidad en el manejo de la enfermedad inflamatoria intestinal

Simple item page
dc.creatorQuera, Rodrigo
dc.creatorNúñez F, Paulina
dc.creatorFlores, Lilian
dc.creatorCarvajal, Francisca
dc.creatorCórdova, Andrea
dc.creatorEstay, Camila
dc.date2024
dc.date.accessioned2025-11-18T19:50:49Z
dc.date.available2025-11-18T19:50:49Z
dc.description<p>INTRODUCTION: Despite advancements in therapeutic strategies, corticosteroids continue to play a role in inducing remission in Inflammatory Bowel Disease (IBD). Unfortunately, these drugs are often misused. OBJECTIVES: To assess the dose and duration of corticosteroid therapy,and the subsequent change in treatment among patients with IBD. MATERIALS AND METHODS: We conducted a descriptive, retrospective observational study on patients with IBD under follow-up at the IBD Program of Clínica Universidad de los Andes from January 2021 to August2022. RESULTS: Four hundred and thirty-two IBD were included, with 63% being women,with a median age of 42 years (14-94), 66% had ulcerative colitis (UC). Sixty-six percentageof patients had received corticosteroids during the course of their disease (range 1-9 times) for a median duration of 12 weeks (2-48 weeks), with prednisone being the most frequently used corticosteroids (53%). Seventy-seven percentage of patients had received treatment for over 3 months or in supratherapeutic doses (prednisone &gt; 60 mg day). There was a change in the treatment after the use of corticosteroid in 28% of patients compared to 90% after entering the program (p&lt;0.001, CI95%: 1.83-2.49). During the Program's follow-up, 10% received corticosteroids (71% prednisone, 29% budesonide) with no variations based on IBD type, gender, age, or treatment. No patient received corticosteroids for over 3 months or in supratherapeutic doses in our IBD Program. CONCLUSION: This study emphasizes the importanceof evaluating corticosteroids use as a quality-of -care marker in IBD. The management of these patients through a specialized program could mitigate the excessive use of these drugs.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/c89967b0-e4a3-450f-858e-f6cc8256b38a
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/56813
dc.languagespa
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.sourcevol.44 (2024) date: 2024-10-01 nr.4 p.339-345
dc.titleEvaluación del uso de corticoides como un marcador de atención de calidad en el manejo de la enfermedad inflamatoria intestinalspa
dc.titleAssessment of corticosteroid use as a marker of quality-of-care in the management of inflammatory bowel diseaseeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE